“Our progress in the fourth quarter of 2024 and into 2025 marks a pivotal period for patients, our company, and our investors,” said Thomas Zindrick, President, CEO and Chairman of Genelux (GNLX). “We are pleased with the continued progress and promise of our clinical development program. The strengthening of our management team, with the addition of Matt, and of our balance sheet, with our recent financing, further positions the Company to execute on our mission to transform the lives of patients who need it most.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GNLX:
- Promising Clinical Trial Results and Strong Financial Position Justify Buy Rating for Genelux Corp.
- Genelux, Newsoara announce preliminary Phase 1b/2 data of Olvi-Vec
- Genelux announces alignment with FDA of approval pathway for Olvi-Vec
- Genelux prices 3M shares at $3.50 in underwritten public offering
- One new option listing on February 19th